the efficacy of anti-viral therapy in prevention of recurrence after curative tr

StephenW

<http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2036.2011.04634.x/abstract>

Meta-analysis: the efficacy of anti-viral therapy in prevention of recurrence
after curative treatment of chronic hepatitis B-related hepatocellular carcinoma

J. S.-W. Wong1, G. L.-H. Wong2,3, K. K.-F. Tsoi2,3, V. W.-S. Wong2,3, S. Y.-S.
Cheung1, C.-N. Chong1, J. Wong1, K.-F. Lee1, P. B.-S. Lai1,2, H. L.-Y.
Chan2,3Article first published online: 24 MAR 2011

DOI: 10.1111/j.1365-2036.2011.04634.x
© 2011 Blackwell Publishing Ltd
Issue

Alimentary Pharmacology & Therapeutics
Early View (Articles online in advance of print)

Summary

Background  The role of anti-viral therapy in prevention of hepatocellular
carcinoma (HCC) recurrence is to be defined. Aim  To investigate the role of
anti-viral therapy in prevention of tumour recurrence after curative treatment
of hepatitis B virus (HBV)-related HCC.

Methods  A systematic electronic search on keywords including HCC and
different anti-viral therapies was performed through eight electronic databases,
including Medline, EMBASE and Cochrane Databases. The primary outcome was HCC
recurrence after curative treatment of HBV-related HCC. The secondary outcomes
were mortality related to HCC, mortality related to liver failure and the
overall mortality.

Results  Nine cohort studies were included with a total number of 551
patients: 204 patients with anti-viral treatment group and 347 patients without
anti-viral treatment (control group). There was significant difference in the
incidence of HCC recurrence in favour of the anti-viral treatment group (55% vs.
58%; odds risk (OR) = 0.59, 95% CI 0.35–0.97, P = 0.04). The risk of HCC was
reduced by 41% in the anti-viral treatment group. There were also significant
differences in favour of anti-viral treatment group in terms of liver-related
mortality (0% vs. 8%; OR = 0.13, 95% CI 0.02–0.69, P = 0.02) and overall
mortality (38% vs. 42%; OR = 0.27, 95% CI 0.14–0.50, P < 0.001).

Conclusions  Anti-viral therapy has potential beneficial effects after the
curative treatment of HBV-related hepatocellular carcinoma in terms of tumour
recurrence, liver-related mortality and overall survival. Anti-viral therapy
should be considered after curative treatment of hepatocellular carcinoma.



(6.合.彩).足球.篮球...各类投注开户下注

第一投注.现金网:招代理年薪10万以上:6668.cc

StephenW

Meta分析：抗病毒治疗预防复发效果
慢性乙型肝炎后，有关治疗肝癌的疗效

j的S.-W. Wong1湾L.-H. Wong2，3，光K.-F. Tsoi2，三，五W.-S. Wong2，3，学潘玉生
Cheung1，C.-N. Chong1，J. Wong的一，K.-F. Lee1，体育B.-S.来1，2，阁下L.-Y.
Chan2，3Article首次在网上公布：2011年3月24日

分类号：10.1111/j.1365-2036.2011.04634.x
© 2011布莱克韦尔出版有限公司
发行

消化系统药理学与治疗学
厄尔利维尤（第预先在网上打印）

综述

背景的抗病毒治疗肝癌的预防作用
肝癌（HCC）复发，是被定义。目的研究中的作用
抗病毒治疗在肿瘤治疗后复发的预防治疗
乙型肝炎病毒（HBV）相关肝癌。

方法电子检索系统，包括肝癌和关键字
不同的抗病毒治疗进行到第八电子数据库，
包括Medline，EMBASE和Cochrane资料库。主要结果是肝癌
复发后的HBV相关肝癌治疗服务。次要结果
肝癌相关的死亡率，与肝功能衰竭，死亡率
整体死亡率。

结果九队列研究，包括了总人数551
例：204例抗病毒治疗组和347例无
抗病毒治疗（对照组）。有显着差异，在
肝癌复发率的抗病毒治疗组的青睐（55％比
58％;赔率风险（OR）= 0.59，95％CI为0.35-0.97，P值0.04）。肝癌的危险性
由41％减少了抗病毒治疗组。也有显着
在抗病毒治疗组差异有利于肝相关的术语
死亡率（0％和8％;或= 0.13，95％CI为0.02-0.69，P值0.02）和总
死亡率（38％对比42％;或= 0.27，95％CI为0.14-0.50，磷“0.001）。

结论:抗病毒治疗后有潜在的有利影响
治疗性乙肝病毒相关的肝癌肿瘤条款
复发，肝脏相关死亡率和生存率。
治疗肝癌病
之后，应考虑治抗病毒治疗。